Literature DB >> 21103968

In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy.

Gerhard Burckhardt1, Birgitta Christina Burckhardt.   

Abstract

Organic anion transporters 1-10 (OAT1-10) and the urate transporter 1 (URAT1) belong to the SLC22A gene family and accept a huge variety of chemically unrelated endogenous and exogenous organic anions including many frequently described drugs. OAT1 and OAT3 are located in the basolateral membrane of renal proximal tubule cells and are responsible for drug uptake from the blood into the cells. OAT4 in the apical membrane of human proximal tubule cells is related to drug exit into the lumen and to uptake of estrone sulfate and urate from the lumen into the cell. URAT1 is the major urate-absorbing transporter in the apical membrane and is a target for uricosuric drugs. OAT10, also located in the luminal membrane, transports nicotinate with high affinity and interacts with drugs. Major extrarenal locations of OATs include the blood-brain barrier for OAT3, the placenta for OAT4, the nasal epithelium for OAT6, and the liver for OAT2 and OAT7. For all transporters we provide information on cloning, tissue distribution, factors influencing OAT abundance, interaction with endogenous compounds and different drug classes, drug/drug interactions and, if known, single nucleotide polymorphisms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21103968     DOI: 10.1007/978-3-642-14541-4_2

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  50 in total

Review 1.  OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies.

Authors:  Megan Roth; Amanda Obaidat; Bruno Hagenbuch
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  The role of transporters in the toxicity of nucleoside and nucleotide analogs.

Authors:  Christopher A Koczor; Rebecca A Torres; William Lewis
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-04-18       Impact factor: 4.481

3.  α-Ketoglutarate-related inhibitors of HIF prolyl hydroxylases are substrates of renal organic anion transporters 1 (OAT1) and 4 (OAT4).

Authors:  Yohannes Hagos; Gunnar Schley; Johannes Schödel; Wolfgang Krick; Gerhard Burckhardt; Carsten Willam; Birgitta C Burckhardt
Journal:  Pflugers Arch       Date:  2012-08-09       Impact factor: 3.657

Review 4.  The organic anion transporter (OAT) family: a systems biology perspective.

Authors:  Sanjay K Nigam; Kevin T Bush; Gleb Martovetsky; Sun-Young Ahn; Henry C Liu; Erin Richard; Vibha Bhatnagar; Wei Wu
Journal:  Physiol Rev       Date:  2015-01       Impact factor: 37.312

5.  Main constituents of polyphenol complex from seagrasses of the genus Zostera, their antidiabetic properties and mechanisms of action.

Authors:  Olga Nikolaevna Styshova; Alexander Michailovich Popov; Alexander Alekseevish Artyukov; Anna Anatolievna Klimovich
Journal:  Exp Ther Med       Date:  2017-03-10       Impact factor: 2.447

Review 6.  Expression and function of renal and hepatic organic anion transporters in extrahepatic cholestasis.

Authors:  Anabel Brandoni; María Herminia Hazelhoff; Romina Paula Bulacio; Adriana Mónica Torres
Journal:  World J Gastroenterol       Date:  2012-11-28       Impact factor: 5.742

7.  Combining Extracellular miRNA Determination with Microfluidic 3D Cell Cultures for the Assessment of Nephrotoxicity: a Proof of Concept Study.

Authors:  Laura Suter-Dick; L Mauch; D Ramp; M Caj; M K Vormann; S Hutter; H L Lanz; J Vriend; R Masereeuw; M J Wilmer
Journal:  AAPS J       Date:  2018-07-23       Impact factor: 4.009

Review 8.  Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside.

Authors:  James J Beaudoin; Kim L R Brouwer; Melina M Malinen
Journal:  Pharmacol Ther       Date:  2020-04-02       Impact factor: 12.310

9.  An Essential Role of Nedd4-2 in the Ubiquitination, Expression, and Function of Organic Anion Transporter-3.

Authors:  Da Xu; Haoxun Wang; Guofeng You
Journal:  Mol Pharm       Date:  2015-12-22       Impact factor: 4.939

10.  Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.

Authors:  Matthew L Rizk; Robert Houle; Grace Hoyee Chan; Mike Hafey; Elizabeth G Rhee; Xiaoyan Chu
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.